论文部分内容阅读
目的研究HBV前C/BCP区基因变异对慢性乙型肝炎(CHB)患者特异性细胞毒性T淋巴细胞(CTL)免疫应答的影响。方法采用HBV核心抗原表位肽core18-27,流式细胞术胞内细胞因子(CFC)分析法检测CHB患者外周血单个核细胞(PBMC)中的特异性CTL,对扩增产物进行测序分析。结果54例CHB患者中G1896A突变毒株21例,占38.9%;1762/1764位核苷酸联合突变26例。占48.1%;3位点同时突变毒株13例,占24.1%。3种变异株体外HBV核心抗原表位肽core18-27刺激后,特异性CTL水平[(0.41±0.09)%、(0.36±0.08)%、(0.48±0.08)%]显著高于野毒株[(0.11±0.06)%,P<0.05]。结论G1896A变异及1762/1764位核苷酸联合突变能显著增强特异性CTL水平,在CHB患者病情活动过程中起重要作用。
Objective To investigate the effect of HBV pre-C / BCP gene mutation on the immune response of specific cytotoxic T lymphocytes (CTL) in patients with chronic hepatitis B (CHB). Methods The specific CTLs in peripheral blood mononuclear cells (PBMCs) from patients with CHB were detected by using core antigen epitope peptide core18-27 and flow cytometry (FCM). The amplified products were sequenced. Results In 54 CHB patients, 21 cases were G1896A mutation, accounting for 38.9%; and 1762/1764 nucleotide combination mutation in 26 cases. Accounting for 48.1%; 13 sites simultaneously mutated in 3 sites, accounting for 24.1%. The specific CTL levels of three kinds of mutants were significantly higher than that of wild-type strain [(0.41 ± 0.09)%, (0.36 ± 0.08)%, (0.48 ± 0.08)%] after stimulation with HBV core epitope peptide core18-27 [ (0.11 ± 0.06)%, P <0.05]. Conclusion G1896A mutation and 1762/1764 nucleotide mutation can significantly enhance the level of CTL and play an important role in the pathogenesis of CHB.